ATAI Life Sciences N.V. Stock News

Thursday's announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma's increasing embrace of a long-stigmatized class of medications as alternatives for treating an array of mental health conditions. Several psychedelic substances — LSD, psilocybin (aka magic mushrooms), MDMA, ayahuasca and ibogaine  — are bein...

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies in psychedelic-based therapies, according to analysts at Jefferies, who believe that the deal reflects increasing momentum driven by advancing clinical data and an improving regulatory backdrop. The acquisition, previously announced by Lilly...

AtaiBeckley (ATAI) shares are ripping higher on Thursday morning after pharmaceutical giant Eli Lilly (LLY) said it will acquire the clinical-stage biotechnology firm for up to $3.8 billion. Lilly has agreed to pay $6.75 a share in cash upfront ($2.8 billion) – with an additional $2.5 a share in contingent value rights (CVRs) tied to critical clinical and regulatory milestones.

Eli Lilly tripped into the psychedelics space Thursday with the up-to-$3.8 billion acquisition of AtaiBeckley.

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8 billion, with the deal adding the clinical-stage biotechnology company's pipeline of investigational therapies for treatment-resistant depression and other mental health conditions to Lilly's neuroscience portfolio. Under the terms of the agreeme...

Wall Street looked set for a mixed open Thursday with further yo-yoing in technology stocks amidst a fresh batch of corporate earnings. Futures pointed to the Dow Jones opening 0.2%, while the S&P 500 was called down 0.2% and the Nasdaq looked set to bear the brunt of the selling, with futures off 0.8% as semiconductor stocks see pressure.

Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker's recent buying spree.

Eli Lilly ​said on ‌Thursday it would ​acquire ​psychedelic drug developer ⁠AtaiBeckley ​for up ​to $3.8 billion, entering the ​race ​to develop psychedelic ‌treatments ⁠for depression and other ​mental ​health ⁠disorders.